| Literature DB >> 25250556 |
E Haas1, B C Rütgen, W Gerner, B Richter, A Tichy, A Galler, A Bilek, J G Thalhammer, A Saalmüller, N Luckschander-Zeller.
Abstract
BACKGROUND: Many dogs suffering from inflammatory bowel disease (IBD) are presented to veterinary clinics. These patients are diagnosed based on a history of chronic gastrointestinal signs and biopsy-confirmed histopathologic intestinal inflammation. Intestinal intraepithelial lymphocytes (IEL) are part of the first line of defense in the gastrointestinal immune system. Alterations in IEL subsets may play a role in the pathogenesis of IBD. HYPOTHESIS: The aim of this study was to characterize the phenotypes of IEL in dogs with IBD compared with healthy control dogs. ANIMALS: Intestinal intraepithelial lymphocytes subpopulations of control dogs (n = 5) obtained from endoscopic biopsies (EB) were compared to those obtained from full thickness biopsies (FTB) on the same day. In addition, the phenotypes of IEL from FTB of control dogs (n = 10) were compared with EB of IBD dogs (n = 10). Each participant was scored clinically using the canine inflammatory bowel disease activity index (CIBDAI), and all samples were graded histopathologically. Three-color flow cytometry of isolated IEL was performed using monoclonal antibodies against T- and B-lymphocyte subpopulations.Entities:
Keywords: Dogs; Flow-cytometry; Intestinal immune-cells
Mesh:
Year: 2014 PMID: 25250556 PMCID: PMC4895640 DOI: 10.1111/jvim.12456
Source DB: PubMed Journal: J Vet Intern Med ISSN: 0891-6640 Impact factor: 3.333
List of mAb used for flow cytometry
| mAb | Clone | Isotype | Fluorescence Labeling |
|---|---|---|---|
| CD45 | YKIX716.13 | rIgG2b | APC |
| CD79αcy | HM57 | mIgG1 | PE |
| CD21 | B‐ly‐4 | mIgG1 | APC |
| CD3 | CD3‐12 | rIgG1 | FITC |
| TCRαβ | CA15.8G7 | mIgG1 | α‐mIgG1‐FITC |
| TCRγδ | CA20.8H1 | mIgG2a | α‐mIgG2a‐FITC |
| CD4 | YKIX302.9 | rIgG2a | APC |
| CD8α | YCATE 55.9 | rIgG1 | PE |
| CD8β | CA15.4G2 | mIgG1 | α‐mIgG1‐APC |
mAb, monoclonal antibodies; CD, cluster of differentiation; IgG, immunoglobulin G; TCR, T‐cell receptor; m, mouse; α‐m, anti‐mouse; r, rat; APC, allophycocyanin; FITC, fluorescein isothiocyanate; PE, phycoerythrin.
Anti‐canine antibody.
Anti‐human cross‐reactive antibody (CD79αcy47; CD3‐12: Serotec, technical datasheet MCA1477; CD21).48
Fluorescence labeling was achieved by use of a secondary antibody.
Goat anti‐mouse IgG1‐Alexa488; Life Technologies, Carlsbad, CA.
Goat F(ab′)2 anti‐mouse IgG2a‐FITC; SouthernBiotech, Birmingham, AL.
Goat anti‐mouse IgG1‐Alexa647; Life Technologies.
Figure 1Clinical disease scores for individual dogs in each study group. The canine inflammatory bowel disease activity index (CIBDAI) for control dogs (n = 10) and dogs with inflammatory bowel disease (IBD; n = 10) was calculated for individual dogs. Each dot indicates an individual dog score. The horizontal lines show the mean score in each group (**P < .01).
Figure 2Histopathology scores for individual dogs in each study group. Histopathology grading was performed according to the World Small Animal Veterinary Association (WSAVA) guidelines for control dogs (n = 10) and dogs with inflammatory bowel disease (IBD; n = 10). Each dot indicates an individual dog score. The horizontal lines show the mean score in each group (**P < .01).
Figure 3Flow cytometry histograms for intestinal intraepithelial lymphocytes (IEL) from 1 control dog and 1 inflammatory bowel disease (IBD) dog. Both are representative of their respective dog groups. Cells were gated by forward/sideward scatter (FSC/SSC) properties (A). The IEL were stained with anti‐canine‐specific or anti‐human‐cross‐reactive monoclonal antibodies (mAb) against CD79αcy (B), CD21 (C), CD3‐12 (D), TCRαβ (E), and TCRγδ (F), CD4 (G), CD8α (H) and CD8β (CD8β data not shown). Histograms show negative cells on the left and positive cells on the right side of each border. Borders were set according to the corresponding isotype controls. Numbers indicate positive cells as a percent of CD3+ T‐cells.
Phenotypes of intestinal IEL from control dogs and dogs with IBD, expressed as percent of CD3+ T‐cells
| CD4 | CD8α | TCRαβ | CD8ααTCRαβ | CD8αβTCRαβ | TCRγδ | |
|---|---|---|---|---|---|---|
| Control dogs (n = 10) | ||||||
| IEL, mean ±SD | 14.2 ± 11.1 | 52.9 ± 24 | 79.7 ± 17 | 6.9 ± 3.9 | 44.4 ± 25.4 | 8.4 ± 6.1 |
| IEL, median (range) | 10.5 (4.6–39.1) | 60.7 (15.3–74.8) | 83.4 (44.6–101.4) | 6.9 (2.1–14.8) | 46.1 (11.7–85.9) | 5.8 (0.6–17.7) |
| IBD dogs (n = 10) | ||||||
| IEL, mean ± SD | 7.9 ± 6.3 | 53.1 ± 19.3 | 64.4 ± 15.6 | 6.9 ± 2.4 | 43.7 ± 18.6 | 19.9 ± 8.7 |
| IEL, median (range) | 6.9 (1.1–24.3) | 50.0 (29.2–93.8) | 62.8 (44–96.1) | 5.7 (4.6–11.5) | 43.3 (21.0–84.6) | 21.7 (1.5–29.6) |
IEL, intraepithelial lymphocytes; IBD, inflammatory bowel disease.
Parameters that were not normally distributed were analyzed by the Mann–Whitney test.
Parameters that were normally distributed were analyzed by Student's t‐test.
Significant difference between groups (P < .05).
Figure 4Distribution of TCR (T‐cell receptor)αβ+ and TCRγδ+ T‐cells within intestinal intraepithelial lymphocytes (IEL). Box and whisker plots show TCRαβ and yδ expression within IEL from controls dogs (n = 10) and dogs with inflammatory bowel disease (IBD; n = 10). Each box and whisker plot illustrates the median and quartiles (**P < .01).
Figure 5CD8αα and CD8αβ expression on TCR (T‐cell receptor)αβ+ and TCRγδ+ T‐cells within intestinal intraepithelial lymphocytes (IEL). Analysis of CD8αα homodimers and CD8αβ heterodimers expressed on TCRγδ+ T‐cells (upper contour plots) and TCRγδ− (lower contour plots, classified as TCRαβ+) T‐cells in control dogs and dogs with inflammatory bowel disease (IBD). A representative individual is shown for each dog group. The gating strategy for TCRγδ expression is shown in histograms in the middle plots, and explained in Figure 3.